Pharma Medical News about Papillomavirus Vaccines Gardasil Cervarix

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

FDA Approves Gardasil to Prevent Genital Warts in Males. Agency Also Approves Bivalent HPV Vaccine for Girls, Young Women
American Family Physician, 10/27/09

The FDA has expanded its approval of Merck & Co. Inc.'s quadrivalent human papillomavirus, or HPV, vaccine, which is marketed as Gardasil, to include use of the vaccine to prevent genital warts in boys and men ages 9–26 years. The agency also has given a thumbs–up to a bivalent HPV vaccine for girls and young women. During clinical trials in more than 4,000 males, Gardasil was nearly 90 percent effective in preventing genital warts caused by infection with HPV types 6 and 11. Gardasil was approved in 2006 for use in girls and young women ages 9–26 years for the prevention of cervical cancer, vulvar cancer, vaginal cancer and precancers caused by HPV types 16 and 18; genital warts caused by HPV types 6 and 11; and precancerous or dysplastic lesions caused by HPV types 6, 11, 16, and 18. Merck's vaccine soon will have competition from GlaxoSmithKline Biologicals, or GSK. The FDA approved GSK's bivalent HPV vaccine, Cervarix, on Oct. 16 for the prevention of cervical cancer and precancerous lesions caused by HPV types 16 and 18 in girls and women ages 10–25.

<< Previous
New Study on Vyvanse (lisdexamfetamine dimesylate) Capsules CII...

Next >>
Gileads Aztreonam for Inhalation Solution to be Reviewed by FDA...

New HPV Vaccine Might Stop Vulvar Cancer in Its Tracks
MedLinePlus, 11/06/09 Relevance Score: 88%

ACIP Supports 'Permissive Use,' But Not Routine Use, of Gardasil in Males
American Family Physician, 10/29/09 Relevance Score: 82%

CDC Survey Shows Gains in Overall Adolescent Vaccination Rates for 2008. But Majority Still Lack Immunizations for Tdap, MCV4
American Family Physician, 10/23/09 Relevance Score: 81%

A survey of adolescent experiences of human papillomavirus vaccination in the Manchester study
British Journal of Cancer, 10/09/09 Relevance Score: 81%

U.S. OKs Merck shot to prevent male genital warts
Reuters, 10/19/09 Relevance Score: 80%